Peripheral Neuropathy Trial, Recruiting (NCT07427537)

Peripheral Neuropathy Trial, Recruiting NCT07427537 Sponsor: University Hospital, Clermont-Ferrand Condition: Peripheral Neuropathy

Printed from Voxsanity (voxsanity.com.au) — NCT07427537 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Neuropathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People being treated for colorectal cancer who are scheduled to receive a chemotherapy regimen containing oxaliplatin for at least 6 cycles.
People being treated for lung cancer who are scheduled to receive a chemotherapy regimen containing paclitaxel for at least 4 cycles.

Who may not be able to join:

People who have a neurodegenerative condition, such as Parkinson's disease or Alzheimer's disease.
People who have had a stroke at any point in the past.
People who already have nerve damage or nerve-related symptoms before starting the trial, based on a specific screening score (confirm with trial site).
People who are currently experiencing significant pain, based on a specific pain rating threshold (confirm with trial site).
People who are pregnant or breastfeeding.
People who are under a legal protection arrangement, such as guardianship or curatorship, or who are currently detained or otherwise deprived of liberty.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: David BALAYSSAC, University Hospital, Clermont-Ferrand

Phone: 334.73.754.963

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07427537

Sponsor: University Hospital, Clermont-Ferrand

Phase: Not Applicable

Status: Recruiting

Condition: Peripheral Neuropathy

Trial contact: 334.73.754.963

More information: https://clinicaltrials.gov/study/NCT07427537

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People being treated for colorectal cancer who are scheduled to receive a chemotherapy regimen containing oxaliplatin for at least 6 cycles.
People being treated for lung cancer who are scheduled to receive a chemotherapy regimen containing paclitaxel for at least 4 cycles.

Who may not be able to join:

People who have a neurodegenerative condition, such as Parkinson's disease or Alzheimer's disease.
People who have had a stroke at any point in the past.
People who already have nerve damage or nerve-related symptoms before starting the trial, based on a specific screening score (confirm with trial site).
People who are currently experiencing significant pain, based on a specific pain rating threshold (confirm with trial site).
People who are pregnant or breastfeeding.
People who are under a legal protection arrangement, such as guardianship or curatorship, or who are currently detained or otherwise deprived of liberty.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Hospital, Clermont-Ferrand

Registry

ClinicalTrials.gov

Start date

29 January 2026

Est. completion

31 July 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Blood concentrations of microRNAs and severity score of sensory chemotherapy-induced peripheral neuropathy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov